Format

Send to

Choose Destination
J Leukoc Biol. 2018 Sep;104(3):587-596. doi: 10.1002/JLB.3TA0517-192R. Epub 2018 Apr 18.

Lipofection of plasmid DNA into human mast cell lines using lipid nanoparticles generated by microfluidic mixing.

Author information

1
Nanotechnology Research Centre, National Research Council Canada, Edmonton, Alberta, Canada.
2
Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.

Abstract

Mast cells are important immune cells that have significant roles in mediating allergy and asthma. Therefore, studying the molecular mechanisms regulating these and other processes in mast cells is important to elucidate. Methods such as lipofection, transduction, and electroporation are often employed to dissect these mechanisms by disrupting gene expression in mast cell lines. However, as with other leukocytes, human mast cells (HMCs) are often refractory to the delivery of plasmids by lipofection. In this study, we investigated the utility of lipid nanoparticles (LNPs) containing the ionizable cationic lipids 1,2-dioleoyloxy-3-dimethylaminopropane, 1,2-dioleyloxy-3-dimethylaminopropane, or 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane for the delivery of plasmid DNA into HMC lines. Herein, we demonstrate for the first time the use of LNPs to achieve significant and reproducible levels of plasmid DNA transfection in HMC-1.2 and laboratory of allergic diseases 2 (LAD2) cells. These levels reached 53.2% and 16.0% in HMC-1.2 and LAD2 cells, respectively; and outperformed Lipofectamine 3000 in both cases. Moreover, cell viability in the transfected cells remained above 65% for all LNP conditions tested. Together, these observations illustrate the efficacy of this technique for mast cell researchers and further support the use of LNPs for nucleic acid delivery into leukocytes.

KEYWORDS:

HMC-1.2; LAD2; cationic; delivery; ionizable; transfection

PMID:
29668121
DOI:
10.1002/JLB.3TA0517-192R

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center